Lipid metabolism and the targeting of angiopoietin-like 3 : Experimental drugs under development
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 32(2023), 3 vom: 09. März, Seite 177-180 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Polychronopoulos, Georgios [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ARO-ANG3 |
|---|
| Anmerkungen: |
Date Completed 31.03.2023 Date Revised 10.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13543784.2023.2179480 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352672064 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352672064 | ||
| 003 | DE-627 | ||
| 005 | 20231226054249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2023.2179480 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM352672064 | ||
| 035 | |a (NLM)36757398 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Polychronopoulos, Georgios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipid metabolism and the targeting of angiopoietin-like 3 |b Experimental drugs under development |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2023 | ||
| 500 | |a Date Revised 10.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a ARO-ANG3 | |
| 650 | 4 | |a angiopoietin-like 3 | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a dyslipidemia | |
| 650 | 4 | |a evinacumab | |
| 650 | 4 | |a vupanorsen | |
| 650 | 7 | |a Cholesterol, LDL |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Angiopoietins |2 NLM | |
| 700 | 1 | |a Kostourou, Danai-Thomais |e verfasserin |4 aut | |
| 700 | 1 | |a Tziomalos, Konstantinos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 32(2023), 3 vom: 09. März, Seite 177-180 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:3 |g day:09 |g month:03 |g pages:177-180 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2023.2179480 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 3 |b 09 |c 03 |h 177-180 | ||